MK-6070 also demonstrates antitumor activity in mixed tumors, affecting DLL3-negative prostate cancer cells after engagement with surrounding DLL3-expressing tumor cells, supporting a potential bystander effect. Overall, these data demonstrate the promising activity of MK-6070 in NEPC preclinical models including heterogeneous tumors, supporting the clinical development of MK-6070.

1 month ago

Preclinical • Journal

DLL3 (Delta Like Canonical Notch Ligand 3)

DLL3 expression

gocatamig (MK-6070)

2ms

Preclinical activity of the DLL3-targeted T cell engager MK-6070 in neuroendocrine prostate cancer. (PubMed, Mol Cancer Ther)

MK-6070 also demonstrates anti-tumor activity in mixed tumors, impacting DLL3-negative prostate cancer cells after engagement with surrounding DLL3-expressing tumor cells, supporting a potential bystander effect. Overall, these data demonstrate promising activity of MK-6070 in NEPC preclinical models including heterogeneous tumors, supporting the clinical development of MK-6070.

2 months ago

Preclinical • Journal

DLL3 (Delta Like Canonical Notch Ligand 3)

DLL3 expression

gocatamig (MK-6070)

5ms

A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002) (clinicaltrials.gov)

P1/2, N=242, Recruiting, Merck Sharp & Dohme LLC | N=138 --> 242

5 months ago

Enrollment change

Imfinzi (durvalumab) • ifinatamab deruxtecan (DS-7300) • gocatamig (MK-6070)

6ms

Harnessing delta-like ligand 3: bridging biomarker discovery to next-generation immunotherapies in refractory small cell lung cancer. (PubMed, Front Immunol)

The 2024 FDA approval of tarlatamab-a bispecific T-cell engager (BiTE) targeting DLL3 and CD3-marks a pivotal advancement, demonstrating improvement in survival in refractory disease. This review examines three key advances reshaping SCLC management: (1) mechanistic links between DLL3-driven tumorigenesis and PD-L1-mediated immunosuppression, (2) clinical progress in antibody-drug conjugates (ADCs) with next-generation payloads (e.g., FZ-AD005), multispecific BiTEs (e.g., HPN328), and engineered CAR-T/NK cells with enhanced metabolic resilience, and (3) precision strategies combining liquid biopsy for dynamic DLL3 profiling with immuno-PET imaging using [89Zr]Zr-DFO-SC16. Emerging synergies, such as combining DLL3-targeted BiTEs with ICIs to amplify T-cell infiltration or reprogramming CAR-T mitochondrial metabolism, further underscore the potential of multimodal approaches. Together, these developments signal a transformative era in SCLC treatment, where molecular diagnostics and engineered immunotherapies converge to address unmet clinical needs.

6 months ago

Review • Journal • PD(L)-1 Biomarker • IO biomarker

PD-L1 (Programmed death ligand 1) • DLL3 (Delta Like Canonical Notch Ligand 3)

Imdelltra (tarlatamab-dlle) • gocatamig (MK-6070)

7ms

P1/2, N=138, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: Oct 2028 --> Aug 2029 | Trial primary completion date: Oct 2028 --> Aug 2029

7 months ago

Trial completion date • Trial primary completion date

ifinatamab deruxtecan (DS-7300) • gocatamig (MK-6070)

8ms

A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001) (clinicaltrials.gov)

P1/2, N=232, Recruiting, Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Trial completion date: Jun 2027 --> Nov 2027 | Trial primary completion date: Jun 2027 --> Nov 2027

8 months ago

Trial completion date • Trial primary completion date

DLL3 (Delta Like Canonical Notch Ligand 3)

DLL3 expression

Tecentriq (atezolizumab) • ifinatamab deruxtecan (DS-7300) • gocatamig (MK-6070)

10ms

P1/2, N=138, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting

10 months ago

Enrollment open

ifinatamab deruxtecan (DS-7300) • gocatamig (MK-6070)

10ms

A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001) (clinicaltrials.gov)

P1/2, N=232, Recruiting, Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Trial completion date: Feb 2026 --> Jun 2027 | Trial primary completion date: Feb 2026 --> Jun 2027

10 months ago

Trial completion date • Trial primary completion date

DLL3 (Delta Like Canonical Notch Ligand 3)

DLL3 expression

Tecentriq (atezolizumab) • ifinatamab deruxtecan (DS-7300) • gocatamig (MK-6070)

11ms

A Study to Evaluate the Safety and Efficacy of MK-6070 and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002) (clinicaltrials.gov)

P1/2, N=138, Not yet recruiting, Merck Sharp & Dohme LLC

11 months ago

New P1/2 trial

ifinatamab deruxtecan (DS-7300) • gocatamig (MK-6070)

over1year

A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001) (clinicaltrials.gov)

P1/2, N=232, Recruiting, Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | N=162 --> 232 | Trial primary completion date: Jul 2025 --> Jan 2026

over 1 year ago

Enrollment change • Trial primary completion date • Metastases

DLL3 (Delta Like Canonical Notch Ligand 3)

Tecentriq (atezolizumab) • ifinatamab deruxtecan (DS-7300) • gocatamig (MK-6070)

over1year

Study in Patients With Advanced Cancers Associated With Expression of DLL3 (clinicaltrials.gov)

P1/2, N=162, Recruiting, Harpoon Therapeutics | Trial completion date: Jun 2024 --> Dec 2025 | Trial primary completion date: Jan 2024 --> Jul 2025

over 1 year ago

Trial completion date • Trial primary completion date • IO biomarker • Metastases

DLL3 (Delta Like Canonical Notch Ligand 3)

Tecentriq (atezolizumab) • gocatamig (MK-6070)